Preferred Label : Tizetatug Rezetecan;
NCIt synonyms : Anti-TROP-2/Antibody-drug Conjugate SHR-A1921; Anti-TROP-2/SHR9265 ADC SHR-A1921; ADC SHR-A1921; Anti-TROP-2 ADC SHR-A1921;
NCIt definition : An antibody-drug conjugate (ADC) composed of an immunoglobulin G1 (IgG1) monoclonal
antibody directed against the tumor-associated antigen (TAA) trophoblast cell surface
protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2;
GA733-1; M1S1) conjugated, via a cleavable linker, to the exatecan derivative and
topoisomerase-1 inhibitor rezetecan, with potential antineoplastic activity. Upon
intravenous administration, the monoclonal antibody moiety of tizetatug rezetecan
targets and binds to TROP-2 expressed on tumor cells. Upon binding, internalization
and linker cleavage, rezetecan is released and inhibits DNA topoisomerase I activity,
thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis
in tumor cells expressing TROP-2. TROP-2 is a transmembrane protein overexpressed
in various tumors. Its expression is associated with enhanced tumor aggressiveness,
metastasis, drug resistance and increased tumor cell survival.;
UNII : UJR3SD8NLS;
CAS number : 2938864-88-9;
Molecule name : SHR-A1921; SHR A1921;
NCI Metathesaurus CUI : CL1913111;
Origin ID : C211811;
concept_is_in_subset
- has_target
